Kevin J. Gould Sells 13,650 Shares of AngioDynamics, Inc. (NASDAQ:ANGO) Stock

Share on StockTwits

AngioDynamics, Inc. (NASDAQ:ANGO) Director Kevin J. Gould sold 13,650 shares of the business’s stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $21.45, for a total value of $292,792.50. Following the sale, the director now owns 61,774 shares of the company’s stock, valued at approximately $1,325,052.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

NASDAQ ANGO opened at $21.19 on Friday. The company has a market capitalization of $788.61 million, a P/E ratio of 25.53 and a beta of 0.69. AngioDynamics, Inc. has a 52 week low of $18.11 and a 52 week high of $25.48. The firm’s 50 day moving average price is $19.94. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.75 and a current ratio of 4.30.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Wednesday, July 10th. The medical instruments supplier reported $0.25 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.26 by ($0.01). The firm had revenue of $96.30 million for the quarter, compared to the consensus estimate of $92.34 million. AngioDynamics had a net margin of 17.06% and a return on equity of 5.58%. The company’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.20 EPS. On average, equities analysts expect that AngioDynamics, Inc. will post 0.27 EPS for the current year.

A number of institutional investors have recently made changes to their positions in ANGO. Nisa Investment Advisors LLC grew its holdings in AngioDynamics by 100.0% during the second quarter. Nisa Investment Advisors LLC now owns 2,200 shares of the medical instruments supplier’s stock worth $43,000 after buying an additional 1,100 shares in the last quarter. Advisor Group Inc. grew its holdings in AngioDynamics by 21.4% during the fourth quarter. Advisor Group Inc. now owns 3,405 shares of the medical instruments supplier’s stock worth $68,000 after buying an additional 601 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in AngioDynamics by 28.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 5,315 shares of the medical instruments supplier’s stock worth $107,000 after buying an additional 1,181 shares in the last quarter. BNP Paribas Arbitrage SA grew its holdings in AngioDynamics by 121.9% during the first quarter. BNP Paribas Arbitrage SA now owns 8,883 shares of the medical instruments supplier’s stock worth $203,000 after buying an additional 4,880 shares in the last quarter. Finally, Piedmont Investment Advisors Inc. bought a new stake in AngioDynamics during the first quarter worth $213,000. Institutional investors and hedge funds own 98.47% of the company’s stock.

ANGO has been the subject of several recent research reports. ValuEngine downgraded Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. BidaskClub upgraded Westport Fuel Systems from a “hold” rating to a “buy” rating in a report on Friday, July 12th. TheStreet downgraded Upland Software from a “b-” rating to a “c+” rating in a report on Wednesday, July 10th. Finally, Zacks Investment Research upgraded Investar from a “hold” rating to a “buy” rating and set a $27.00 price objective for the company in a report on Tuesday, June 4th. Two analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $21.50.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Read More: Trading signals using Bollinger bands

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Wedbush Securities Inc. Sells 160 Shares of Innospec Inc.
Wedbush Securities Inc. Sells 160 Shares of Innospec Inc.
Wedbush Securities Inc. Has $293,000 Position in China Mobile Ltd.
Wedbush Securities Inc. Has $293,000 Position in China Mobile Ltd.
Wedbush Securities Inc. Sells 1,062 Shares of Cedar Fair, L.P.
Wedbush Securities Inc. Sells 1,062 Shares of Cedar Fair, L.P.
Wedbush Securities Inc. Buys New Stake in Aquestive Therapeutics Inc
Wedbush Securities Inc. Buys New Stake in Aquestive Therapeutics Inc
7,019 Shares in D. R. Horton Inc  Bought by Wedbush Securities Inc.
7,019 Shares in D. R. Horton Inc Bought by Wedbush Securities Inc.
Wedbush Securities Inc. Has $294,000 Holdings in Office Properties Income Trust
Wedbush Securities Inc. Has $294,000 Holdings in Office Properties Income Trust


© 2006-2019 Ticker Report